Description: Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely "find & replace" any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
Home Page: www.graphitebio.com
GRPH Technical Analysis
201 Haskins Way
South San Francisco,
CA
94080
United States
Phone:
650 484 0886
Officers
| Name | Title |
|---|---|
| Dr. Joshua Lehrer-Graiwer FACC, M.D. | Pres, CEO & Director |
| Dr. Matthew Porteus M.D., Ph.D. | Academic Founder & Director |
| Dr. Maria Grazia Roncarolo M.D., Ph.D. | Academic Founder & Chair of Scientific Advisory Board |
| Mr. Philip P. Gutry | Chief Bus. Officer |
| Dr. Daniel Dever Ph.D. | Co-Founder & Head of Discovery Research |
| Ms. Alethia Rene Young | Chief Financial Officer |
| Dr. Christine Garrett P.M.P., Ph.D. | Chief of Staff & Sr. VP of Operations |
| Mr. Jerry Cacia | Chief Technical Officer |
| Dr. Jane Grogan Ph.D. | Chief Scientific Officer |
| Stephanie Yao | VP of Communications & Investor Relations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.3697 |
| Price-to-Book MRQ: | 0.6064 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 114 |